Rostock, March 18th, 2021 Dear customers, we are pleased to inform you about an important change of our gDNA-, cfDNA-, cfDNA in plasma-, plasma- and FFPE-products. The results of our stability studies according to the requirements of DIN EN ISO 23640:2015-12 (shelf life testing of reagents for in vitro diagnostic use) allow us to extend … Read More
Author: sales
Pathogen diagnostic reference materials
Rostock, October 14th, 2020, SensID and Noscendo combine forces to develop a contamination-free reference material with known human DNA quantity and virus status for clinical system validation. The reference material is developed by SensID and tested by Noscendo to be positive for standard microbial DNA and completely free of contaminating microbial DNA. The reference materials will serve … Read More
SAGA Diagnostics and SensID collaborate on ultra-low allelic frequency control reagents for cancer mutations
Rostock and Lund, 15 of July 2020 SensID GmbH, headquartered in Rostock, Germany, is a specialist for development and production of reference control materials for clinical genomics. SAGA Diagnostics AB, headquartered in Lund, Sweden, is a cancer genomics company focused on precision oncology and ultrasensitive liquid biopsy monitoring of cancer patients. Today the two companies announce a … Read More
SARS-CoV-2 Immunity – Rottendorf Pharma Counts on the Competence of SensID
Ennigerloh & Rostock, May 5th, 2020 – SensID GmbH is a leading specialist in quality diagnostics and offers a SARS-CoV-2 immunity testing service to all interested companies (and their staff) as part of an initiative of the State of Mecklenburg-Western Pomerania (to cope with the economic consequences of the pandemic). Rottendorf Pharma, with its headquarters … Read More
SensID product development in collaboration with Qiagen
Rostock, 7th of April 2020 SensID GmbH, a Germany based provider of controls and reference materials for clinical genomics, today announces that it has developed a set of controls for the US FDA approved and CE-IVD marked therascreen PIK3CA RGQ PCR Kits from QIAGEN. The CE-IVD therascreen PIK3CA RGQ PCR Kit was launched in Europe in February 2020 as an aid to the identification of activating PIK3CA mutations in samples of either FFPE tumour tissue or … Read More